LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Abstract 6235: Discovery of novel HDAC6 inhibitors that enhance proteasomal activity to boost antigen presentation and trigger anti-myeloma T-cell immunity

Photo by xteemu from unsplash

Transformative success of cancer immunotherapy has revolutionized cancer treatment and can induce long lasting responses in patients with cancers from a wide range of histologies. However, only a fraction of… Click to show full abstract

Transformative success of cancer immunotherapy has revolutionized cancer treatment and can induce long lasting responses in patients with cancers from a wide range of histologies. However, only a fraction of patients respond to immunotherapy and cancer cells escape immunosurveillance through molecular mechanisms that remain elusive. Proteasomes play a central role in the immune response by generating peptides from intracellular antigens which are presented on the cell surface for recognition by CD8+ cytotoxic T lymphocytes (CTLs). Malignant cells employ strategies to downregulate antigen presentation and impair CTL-mediated tumor recognition and lysis. Recently, we discovered that HDAC6-specific inhibitors increased intracellular proteasome activity and the generation of antigenic class I MHC peptides. However, current HDAC6 inhibitors have pharmacologic liabilities that limit efficacy, e.g., low potency and solubility, poor pharmacokinetic properties and potential genotoxicity. Therefore, we performed a cell-based, high-throughput screen (HTS) of 9,600 HDAC-specific compounds to identify novel compounds that increased proteasomal activity in myeloma cells. We identified 8 hits that increased proteasomal activity at least two-fold. Importantly, two novel molecules identified in the HTS increased proteasome activity more potently and more rapidly than the HDAC6-specific inhibitors Tubastatin-A and ACY-1215 (Ricolinostat) with comparatively low cytotoxicity. Proteasomes degrade chicken ovalbumin (Ova) to generate the immunodominant antigen SIINFEKL presented at the cell surface complexed with the MHC-class I molecule H-2Kb. Treatment of tumor cells with Tubastatin-A and ACY-1215 increased levels of the MHC-class I-SIINFEKL complex by ~3-fold. Tumor cells were pretreated with Tubastatin-A and ACY-1215 and then co-cultured with CTLs that had been genetically-engineered to express a SIINFEKL-restricted T-cell receptor (TCR). Pre-treatment of lymphoma or multiple myeloma cells with novel HDAC6 inhibitors also increased tumor lysis by CTLs that expressed the SIINFEKL-restricted TCR by 2-fold. Taken together, our results support repositioning pharmacologics that inhibit HDAC6 to activate proteasomal generation of antigenic peptides and boost antigen presentation as cancer immunotherapeutics. Citation Format: Priyanka S. Rana, James Ignatz-Hoover, James J. Driscoll. Discovery of novel HDAC6 inhibitors that enhance proteasomal activity to boost antigen presentation and trigger anti-myeloma T-cell immunity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6235.

Keywords: cell; hdac6 inhibitors; antigen presentation; activity; cancer

Journal Title: Cancer Research
Year Published: 2023

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.